PhaseBio Pharmaceuticals, Inc.

PHAS · NASDAQ
Analyze with AI
6/30/2022
3/31/2022
12/31/2021
9/30/2021
Operating Activities
Net Income-$16,665-$11,141$87,830-$31,924
Dep. & Amort.$603$601$606$130
Deferred Tax$0$0$0$0
Stock-Based Comp.$715$597$150$720
Change in WC$9,562-$9,087$7,995$20,162
Other Non-Cash-$4,626-$3,854-$116,575$4,780
Operating Cash Flow-$10,411-$22,884-$19,994-$6,132
Investing Activities
PP&E Inv.-$58-$49-$1,656-$638
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$58-$49-$1,656-$638
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$735$1,185$18-$15
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$415-$179$7,093-$1,329
Financing Cash Flow-$415-$179$7,093-$1,329
Forex Effect$0$0$0$0
Net Chg. in Cash-$10,884-$23,112-$14,557-$8,099
Supplemental Information
Beg. Cash$18,688$41,800$56,357$64,456
End Cash$7,804$18,688$41,800$56,357
Free Cash Flow-$10,469-$22,933-$21,650-$6,770